FDA Approves SpringWorks' Gomekli for Adult and Pediatric NF1-PN Patients on February 13, 2025 Approved Gomekli Inhibitor MEK mirdametinib neurofibroma Plexiform SpringWorks United States Food and Drug Administration +
SpringWorks Therapeutics Secures FDA Approval for Gomekli to Treat NF1-Related Tumors on February 12, 2025 Approved disease treatment Gomekli Infrequent Inhibitor MEK mirdametinib Neurofibromatosis 1 Plexiform Plexiform Neurofibroma SpringWorks United States Food and Drug Administration +